Incyte Corporation (INCY)
| Market Cap | 12.81B |
| Revenue (ttm) | 3.77B |
| Net Income (ttm) | 745.44M |
| Shares Out | 224.54M |
| EPS (ttm) | 3.30 |
| PE Ratio | 17.29 |
| Forward PE | 11.81 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,676,005 |
| Open | 57.60 |
| Previous Close | 57.60 |
| Day's Range | 56.85 - 58.11 |
| 52-Week Range | 50.27 - 67.36 |
| Beta | 0.69 |
| Analysts | Buy |
| Price Target | 73.77 (+29.31%) |
| Earnings Date | Apr 30, 2024 |
About INCY
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast ... [Read more]
Financial Performance
In 2023, Incyte's revenue was $3.70 billion, an increase of 8.87% compared to the previous year's $3.39 billion. Earnings were $597.60 million, an increase of 75.42%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for INCY stock is "Buy." The 12-month stock price forecast is $73.77, which is an increase of 29.31% from the latest price.
News
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASCO24--Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress.
S&P 500 Gains and Losses Today: Incyte Stock Pops on Buyback Plan
Major U.S. equities indexes were mixed and little changed Monday to kick off a new trading week that will provide investors with a few key economic data points.
Incyte to buy back $1.67 billion of its own stock in Dutch auction tender
Biotech Incyte Corp. said Monday its board has approved a share buyback of up to $2 billion and the company has commenced a modified Dutch auction tender for up to $1.67 billion worth.
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock.
Incyte to Present at Upcoming Investor Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 at 8:00 a.m. (PDT)...
Incyte misses quarterly profit on weak sales of lead drug
Incyte Corp on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%.
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs.
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
WILMINGTON, Del. & SAN DIEGO--(BUSINESS WIRE)---- $INCY--Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists.
Incyte to Report First Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 30, 202...
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
WILMINGTON, Del. and HONG KONG--(BUSINESS WIRE)---- $INCY--Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia.
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
HONG KONG, China and WILMINGTON, Del., April 01, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) and Incyte (Nasdaq:INCY) (“Incyte”) are pleased to announce that ...
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2024--Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis.
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2024--Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa.
New Data from Incyte's Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2024--New Data from Incyte's Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting.
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients' Lives through Generative AI
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced the launch of The Unseen Journey, a program that brings to life the hidden emotional and physical toll of myeloproliferative ne...
Knight Therapeutics Announces Launch of Minjuvi® in Brazil
MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitam...
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for ax...
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities.
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®).
Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Report Fourth Quarter and Year-End 2023 Financial Results.
Here are Wall Street's favorite stocks in the sector expected to grow profits the most in 2024
Each earnings reporting season, you can count on a flurry of articles with headlines saying companies “beat” consensus estimates for quarterly profits. But that “success” alone means nothing.
Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference.
